Therapeutic Pipeline

From Data to Drug:
Real Assets

Accelerating discovery with QUAI Platform. We have secured validated candidates for Hair Loss and Sarcopenia.

Development Status

Code Indication Target/MoA
DiscoveryLead OptPre-clinicalPhase 1
GOBT-101 Alopecia AR & DHT Block
Lead Optimization
GOBT-201 Sarcopenia Apelin Pathway
Discovery
GOBT-301 Progeria Rare Genetic
Target ID

LEAD ASSET

GOBT-101

Dual-Action Peptide for Alopecia

AI Designed
Quantum Optimized

GOBT-101 is a revolutionary peptide that provides both hair growth promotion and hair loss prevention. Optimized by Quantum Computing after AI design, it exhibits superior binding affinity and stability.

Modality
Peptide
Status
Open for L/O

Mechanism of Action (MoA)

  • Blocking: Prevents the binding of DHT to Androgen Receptor (AR).
  • Activation: Activates Wnt/β-catenin signaling to stimulate follicles.
  • Result: Simultaneous prevention of regression and promotion of regrowth.

EMERGING ASSET

GOBT-201

Combating Age-Related Muscle Loss

Quantum Designed
AI Optimized

Sarcopenia is a critical challenge in the aging society. GOBT-201 specifically targets the Apelin Pathway to enhance mitochondrial biogenesis and restore muscle mass.

Indication
Sarcopenia
Market Size
$3.2B (2028 Est)

Interested in Licensing?

We offer flexible partnership models for our pipeline assets.


Contact Business Development

전화상담
070-4712-9090
메일문의
info@geneon.kr
KAKAO TALK
CONTACT US
▲ TOP
tel:070-4712-9090
mailto:info@geneon.kr
https://pf.kakao.com/_TWxexhs/chat
/contact-us/